S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33
S&P 500   4,057.84
DOW   32,637.19
QQQ   299.33

Xencor (XNCR) Stock Forecast, Price & News

+0.13 (+0.58%)
(As of 05/26/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
225,277 shs
Average Volume
338,053 shs
Market Capitalization
$1.33 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

Xencor logo

About Xencor

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.


Xencor (NASDAQ:XNCR) Price Target Cut to $42.00
Xencor (NASDAQ:XNCR) PT Lowered to $66.00
Xencor (NASDAQ:XNCR) Shares Gap Up on Strong Earnings
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$275.11 million
Cash Flow
$1.57 per share
Book Value
$12.81 per share


Net Income
$82.63 million
Pretax Margin




Free Float
Market Cap
$1.33 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.31 out of 5 stars

Medical Sector

262nd out of 1,424 stocks

Pharmaceutical Preparations Industry

98th out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Xencor (NASDAQ:XNCR) Frequently Asked Questions

Is Xencor a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xencor stock.
View analyst ratings for Xencor
or view top-rated stocks.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Xencor

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating the consensus estimate of ($0.70) by $1.09. The biopharmaceutical company earned $85.50 million during the quarter, compared to the consensus estimate of $26.17 million. Xencor had a trailing twelve-month return on equity of 15.74% and a net margin of 33.28%. The firm's quarterly revenue was up 152.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) EPS.
View Xencor's earnings history

What price target have analysts set for XNCR?

8 brokerages have issued 12 month price objectives for Xencor's stock. Their forecasts range from $42.00 to $60.00. On average, they anticipate Xencor's stock price to reach $52.33 in the next year. This suggests a possible upside of 134.0% from the stock's current price.
View analysts' price targets for Xencor
or view top-rated stocks among Wall Street analysts.

Who are Xencor's key executives?
Xencor's management team includes the following people:
  • Bassil I. Dahiyat, President, Chief Executive Officer & Director (LinkedIn Profile)
  • John J. Kuch, Chief Financial Officer & Senior Vice President
  • John R. Desjarlais, Chief Scientific Officer & Senior VP-Research
  • Allen Yang, Chief Medical Officer & Senior Vice President
  • Celia Eckert, Secretary, General Counsel & Vice President
What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor CEO Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among Xencor's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.76%), Vanguard Group Inc. (10.74%), Primecap Management Co. CA (8.30%), State Street Corp (4.99%), Loomis Sayles & Co. L P (3.05%) and Dimensional Fund Advisors LP (1.56%). Company insiders that own Xencor stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch.
View institutional ownership trends for Xencor

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Federated Hermes Inc., South Dakota Investment Council, Primecap Management Co. CA, Citigroup Inc., Bank of New York Mellon Corp, TD Asset Management Inc., and Strs Ohio. Company insiders that have sold Xencor company stock in the last year include Allen Yang, Bassil I Dahiyat, Celia Eckert, and John J Kuch.
View insider buying and selling activity for Xencor
or view top insider-selling stocks.

Which institutional investors are buying Xencor stock?

XNCR stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Invesco Ltd., Assenagon Asset Management S.A., Loomis Sayles & Co. L P, Tekla Capital Management LLC, Dimensional Fund Advisors LP, and Granahan Investment Management LLC.
View insider buying and selling activity for Xencor
or or view top insider-buying stocks.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $22.36.

How much money does Xencor make?

Xencor has a market capitalization of $1.33 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $1.779990 on an earnings per share basis.

How many employees does Xencor have?

Xencor employs 254 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at [email protected], or via fax at 626-305-0350.

This page was last updated on 5/27/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.